In Vitro Diagnostic (IVD) In Cardiology And Neurology Global Market Report 2024

The in vitro diagnostic (IVD) in cardiology and neurology market size has grown strongly in recent years. It will grow from $14.58 billion in 2023 to $15.84 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the increasing burden of cardiovascular diseases (CVDs) and neurological disorders, such as stroke and Alzheimer's disease, rise in the prevalence of age-related cardiovascular and neurological disorders, rise in the aging population, growing emphasis on preventive healthcare and early disease detection, rise in supportive regulatory frameworks governing the approval and reimbursement of diagnostic tests and rise in investments in healthcare infrastructure.

The in vitro diagnostic (IVD) in cardiology and neurology market size is expected to see strong growth in the next few years. It will grow to $22.18 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The anticipated growth in the forecast period can be attributed to several factors, including the transition towards personalized medicine in cardiology and neurology, heightened demand for swift and on-site testing solutions within these fields, the expansion of telemedicine and remote consultation services, and an increase in research endeavors. Significant trends expected during this period encompass the emergence of liquid biopsy technologies, progress in nanotechnology applications, the adoption of remote monitoring devices such as implantable cardiac monitors and brain-computer interfaces, utilization of multiplex biomarker panels, advancements in medical imaging modalities such as MRI, CT, and PET scans, and the development of companion diagnostics tailored for cardiovascular and neurological medications.

The expansion of personalized medicine is poised to drive the advancement of the in vitro diagnostic (IVD) market in cardiology and neurology in the foreseeable future. Personalized medicine, which customizes healthcare interventions and treatments to suit the unique characteristics of individual patients, is gaining momentum due to progress in genomics, enhanced understanding of disease mechanisms, patient demand for tailored therapies, and regulatory backing, among other factors. In cardiology and neurology, IVD tests play a pivotal role in facilitating personalized medicine by furnishing essential insights into an individual's genetic composition and disease status. These insights guide the development of customized treatment strategies, thereby enhancing efficacy and minimizing risks. For instance, data from the Personalized Medicine Coalition indicates that in 2022, approximately 34% of all newly approved therapies were personalized medicines, marking a significant rise from previous years. Hence, the escalating adoption of personalized medicines is propelling the growth of the in vitro diagnostic (IVD) market in cardiology and neurology.

Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are innovating AI-driven integrated epigenetic systems to enable early detection of diseases and assess risks. These AI-enabled integrated epigenetic systems utilize machine learning and advanced biomarker analysis methods to improve the precision and sensitivity of diagnosing and monitoring cardiovascular conditions, thereby targeting key factors influencing disease advancement. For example, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology firm, introduced PrecisionCHD, an AI-powered blood test engineered for the timely identification of coronary heart disease (CHD). Employing the company's integrated epigenetic-genetic engine, this test evaluates CHD susceptibility and strives to preemptively detect the most prevalent cardiovascular ailment. Combining epigenetic and genetic indicators with machine learning algorithms, the new test delivers over 75% sensitivity for both genders. It establishes a connection between a patient's biomarker profile and modifiable risk elements, such as smoking, diabetes, hypertension, and elevated cholesterol levels, which significantly contribute to CHD. PrecisionCHD presents a non-invasive option to conventional methods such as exercise stress tests or angiograms, as it requires blood samples collected either at the clinic or home.

In September 2021, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., a Chinese company known for its medical devices and solutions, purchased HyTest Ltd. for $661 million. Through this acquisition, Mindray aims to bolster its position in the in-vitro diagnostics (IVD) sector by leveraging HyTest's proficiency in antibodies and antigens, particularly in areas such as cardiac markers, inflammation, tumor markers, and infectious diseases. HyTest Ltd., headquartered in Finland, specializes in diagnostic test materials, including in vitro diagnostic biomarkers for cardiology.

Major companies operating in the in vitro diagnostic (IVD) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience.

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the in vitro diagnostic (IVD) in cardiology and neurology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

In vitro diagnostic (IVD) in cardiology and neurology involves conducting medical tests on samples such as blood, urine, or tissue outside the body to diagnose a range of cardiovascular and neurological ailments. These tests are pivotal for detecting conditions such as heart disease, stroke, Alzheimer's disease, and more, aiding in early diagnosis, ongoing monitoring, and treatment planning. They offer timely diagnostic insights crucial for guiding patient care and enhancing outcomes in both cardiology and neurology.

The main products of in vitro diagnostic (IVD) in cardiology and neurology encompass instruments, reagents and consumables, and software and services. Instruments denote the tools or apparatuses utilized for conducting diagnostic examinations and scrutinizing patient specimens within laboratory environments. These encompass various technologies such as immunoassays, molecular diagnostics, and hematology, catering to the needs of hospitals, clinical laboratories, and similar entities.

The in vitro diagnostic (IVD) in cardiology and neurology market research report is one of a series of new reports that provides in vitro diagnostic (IVD) in cardiology and neurology market statistics, including the in vitro diagnostic (IVD) in cardiology and neurology industry global market size, regional shares, competitors with in vitro diagnostic (IVD) in cardiology and neurology market share, detailed in vitro diagnostic (IVD) in cardiology and neurology market segments, market trends, and opportunities, and any further data you may need to thrive in the in vitro diagnostic (IVD) in cardiology and neurology industry. This in vitro diagnostic (IVD) in cardiology and neurology market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The in vitro diagnostic (IVD) in cardiology and neurology market consists of revenues earned by entities by providing services such as point-of-care testing, laboratory testing, molecular diagnostics, and biomarker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.